Opexa Therapeutics

Opexa Therapeutics

Biotechnology Research Opexa Therapeutics, Inc. 29 employees OPXA
Employees
29
Contacts
1
Emails
1
Phones
1

Opexa Therapeutics Overview

Headquarters
Opexa Therapeutics, Inc.
Phone Number
Available in AeroLeads
Industry
Biotechnology Research
Employees
29
Stock Symbol
OPXA
Funding
650.0K
Company Email
Available in AeroLeads
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords

About Opexa Therapeutics

Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the development of personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis as well as other autoimmune diseases, such as neuromyelitis optica. These therapies are based on Opexa's proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016. Opexa’s mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.

Opexa Therapeutics Contact Details

People in AeroLeads
1
With contact data
1
Email contacts
1
100.0% coverage
Phone contacts
1
100.0% coverage

Opexa Therapeutics Org Chart

Sample employees and titles
Name Title Contact
Marianne Pfeil Quality Control Laboratory Technician
Email Phone

Employees by Management Level

Individual contributor 11 profiles
Manager 4 profiles
Executive 1 profile
Director 1 profile
Senior / Lead 1 profile
Associate / junior 1 profile

Department Contact Coverage

Department Contacts Email Phone
General 1 1 1
Executive 1 1 1
Sales 1 1 0
IT 1 1 0

Opexa Therapeutics Tech Stack

Compare Similar Companies to Opexa Therapeutics